|
業務類別
|
Biotechnology |
|
業務概覽
|
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates. |
| 公司地址
| 1000 Park Forty Plaza, New York, NC, USA, 27713 |
| 電話號碼
| +1 917 410-3120 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.immunovant.com |
| 員工數量
| 315 |
| Mr. Christopher A. Van Tuyl |
Chief Legal Officer and Corporate Secretary |
美元 495.00K |
22/07/2026 |
| Mr. Tiago M. Girao |
Chief Financial Officer and Chief Accounting Officer |
美元 455.49K |
22/07/2026 |
| Dr. Jay S. Stout, PhD |
Chief Technology Officer |
美元 495.00K |
22/07/2026 |
| Dr. Eric Venker, M.D.,Pharm.D. |
Director and Chief Executive Officer |
美元 636.62K |
22/07/2026 |
| Ms. Melanie Gloria |
Chief Operating Officer |
美元 495.00K |
22/07/2026 |
|
|
| Mr. Andrew J. Fromkin |
Director |
22/07/2026 |
| Dr. Atul Pande, M.D. |
Independent Director |
22/07/2026 |
| Dr. Frank M. Torti, M.D. |
Executive Chairman of the Board |
22/07/2026 |
| Mr. Douglas J. Hughes |
Independent Director |
22/07/2026 |
| Dr. Eric Venker, M.D.,Pharm.D. |
Director and Chief Executive Officer |
22/07/2026 |
| Mr. Robert Susman |
Independent Director |
22/07/2026 |
| Mr. Jacob Bauer |
Independent Director |
22/07/2026 |
|
|
|
|
